drugset / Trial / NCT07077395
Finding Links Between Hot flASHes and CardioVascular Disease
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The goal of this clinical trial is to learn if neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improves blood vessel health in women with moderate to severe hot flashes. The main questions it aims to answer is does neurokinin-1/neurokinin-3 receptor antagonist elinzanetant improve blood vessel health?
Timeline
- Start
- 2026-03-01
- Primary completion
- 2029-06
- Completion
- 2029-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Elinzanetant | Small molecule | 120 mg | — |
Indications
No indication recorded.